ATC Group: N03AX21 Retigabine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N03AX21 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N03 Antiepileptics
3 N03A Antiepileptics
4 N03AX Other antiepileptics
5 N03AX21 Retigabine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.9 g

Active ingredients in N03AX21

Active Ingredient Description
Retigabine

In vitro studies indicate that retigabine acts primarily through opening neuronal potassium channels. This stabilises the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of epileptiform action potential bursts. The mechanism of action of retigabine on potassium channels has been well documented, however other mechanisms by which retigabine may assert an antiepileptic effect have yet to be fully elucidated.

Related product monographs

Title Information Source Document Type  
TROBALT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Estonia (EE)

Lithuania (LT)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.